Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.
Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T, Kirchhofer D, Meier-Menches SM, Hohenwallner K, Schaier M, Rampler E, Koellensperger G, Heffeter P, Keppler B, Berger W. Baier D, et al. Among authors: keppler b. Pharmaceutics. 2022 Jan 20;14(2):238. doi: 10.3390/pharmaceutics14020238. Pharmaceutics. 2022. PMID: 35213972 Free PMC article.
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Körner W, Sevelda F, Micksche M, Keppler BK, Berger W. Heffeter P, et al. Among authors: keppler bk. J Pharmacol Exp Ther. 2005 Jan;312(1):281-9. doi: 10.1124/jpet.104.073395. Epub 2004 Aug 26. J Pharmacol Exp Ther. 2005. PMID: 15331656
Resistance against novel anticancer metal compounds: differences and similarities.
Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski MS, Elbling L, Micksche M, Keppler B, Berger W. Heffeter P, et al. Among authors: keppler b. Drug Resist Updat. 2008 Feb-Apr;11(1-2):1-16. doi: 10.1016/j.drup.2008.02.002. Epub 2008 Apr 3. Drug Resist Updat. 2008. PMID: 18394950 Review.
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).
Heffeter P, Popovic-Bijelic A, Saiko P, Dornetshuber R, Jungwirth U, Voevodskaya N, Biglino D, Jakupec MA, Elbling L, Micksche M, Szekeres T, Keppler BK, Gräslund A, Berger W. Heffeter P, et al. Among authors: keppler bk. Curr Cancer Drug Targets. 2009 Aug;9(5):595-607. doi: 10.2174/156800909789056962. Epub 2009 Aug 1. Curr Cancer Drug Targets. 2009. PMID: 19508176 Free PMC article.
513 results